The company, which houses its U.S. headquarters in Marlborough, Mass., is developing a subcutaneous insulin patch called the CeQur device for Type 2 diabetes.
The company is led by James Peterson, the former CEO of Braintree, Mass.-based Haemonetics Corp.
Milledge spent more than 34 years at Johnson & Johnson Corp., where he served as group president for LifeScan, which produces blood glucose meters, test strips and diabetes management software. The subsidiary employs more than 2,500 workers globally.
Milledge has board affiliations with three other companies: Orthobond Inc., a North Brunswick, N.J.-based company that makes bio-interfaces for medical devices; DFB Pharmaceuticals Inc., a specialty pharmaceutical company out of Ft. Worth, Texas; and NFocus Neuromedical Inc., a startup that’s developing treatments for hemorrhagic stroke in Palo Alto, Calif.
Milledge’s presence on the CeQur board could set the table for a future acquisition of the company.
During his tenure at LifeScan, Milledge led the company through two major M&A deals, when the company bought out Animas Corp. and Inverness Medical Innovations, the latter a $1.3 billion deal. Milledge lists mergers and acquisitions as a specialty on his LinkedIn profile.